March 03, 2022
Teva and Gilead urged a California federal judge Thursday to trim some state claims from United Healthcare's suit alleging the pair overcharged for HIV drugs by delaying cheaper generic versions, saying that consumer protection laws in some states named in the complaint do not extend to corporations or insurance companies.
January 14, 2022
A California federal judge has trimmed antitrust claims that retailers including Walgreens and CVS filed against Teva over alleged overcharges for HIV drugs, saying any claims stretching back more than four years from their lawsuits are time-barred.
January 05, 2022
Teva Pharmaceuticals urged a California federal judge Wednesday to curb antitrust claims brought by Walgreens, CVS and other retailers alleging that the pharmaceutical giant conspired with rival Gilead to keep generic versions of blockbuster HIV treatments off the market, arguing that some of the retailers' claims are time-barred.
November 05, 2021
Bristol-Myers Squibb has reached a $10 million settlement to escape claims that it conspired with rivals to keep a blockbuster HIV treatment off the market, and both sides are hoping that a California federal judge will preliminarily bless the deal.
July 29, 2020
A California federal judge dismissed attempts to revive allegations of an antitrust conspiracy involving Gilead, Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high in a decision unsealed Wednesday that nevertheless left intact key parts of the complaint.
July 16, 2020
Gilead Sciences urged a California federal judge Thursday to nix AIDS activists and consumers' renewed allegations that it engaged in anti-competitive conduct with Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high, arguing the plaintiffs have failed to properly identify a product market.
June 03, 2020
Pharmaceutical giants accused of working together to block generic competition for blockbuster HIV treatments are using their latest motion to dismiss to rehash arguments the California federal court has already dealt with, the proposed class said Tuesday.
May 05, 2020
Gilead Sciences, Bristol-Myers Squibb Co. and Janssen Pharmaceuticals urged a California federal judge Monday to toss newly rejiggered parts of an antitrust complaint alleging that they conspired to block competition for blockbuster HIV treatments, arguing that none of the failings that doomed part of the original complaint has been fixed.
March 04, 2020
Gilead Sciences and several other drug companies remain mired in a sprawling lawsuit alleging they conspired to block competition for blockbuster HIV treatments, after a California federal judge issued a mixed ruling on their dismissal bids.
October 28, 2019
The Federal Trade Commission has waded into a lawsuit accusing Gilead Sciences Inc. of creating an HIV drug empire by using shadowy deals to block generic competition, assailing the company's argument that only one product market is relevant to the case.